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Is guaifenesin safe 
during pregnancy?
It’s	not	clear;	little	evidence	supports	
or	refutes	the	safety	of	guaifenesin,	a	
common	expectorant,	in	pregnancy.	
A	small	number	of	observational	and	
case-control	studies	suggest	a	weak	
association	between	guaifenesin	use	
and	inguinal	hernias	and	neural	tube	
defects	in	newborns.	However,	substantial	
methodological	flaws,	the	absence	of	
statistical	significance,	and	low	rates	of	
prevalence	cast	a	shadow	of	a	doubt	over	
the	data	(strength	of	recommendation	
[sor]:	B,	based	on	observational	and	
case-control	studies).
Always take a conservative approach  
to obstetrics
In	my	practice	as	a	family	physician,	a	
conservative	approach	to	obstetrical	
care	has	been	the	rule.	It	seems	prudent	
to	avoid	guaifenesin	during	the	first	
trimester.	Although	the	evidence	is	
inconclusive	on	potential	harm	to	the	
fetus,	the	marginal	benefit	gained	seems	
insufficient	to	justify	treatment	early	
in	pregnancy	when	the	fetus	is	most	
vulnerable	to	teratogenic	effects	in	
general.		
	 As	with	most	other	Category	C	
medications	(except	those	with	clear	
clinical	benefit	and	no	safer	alternative),	
I	typically	avoid	guaifenesin	throughout	
pregnancy.	However,	it	may	be	
reasonable	to	prescribe	it	in	the	latter	half	
of	pregnancy	when	the	potential	risk	is	
lower;	particularly	in	light	of	the	lack	of	
any	clear	evidence	demonstrating	harmful	
effects.
Christopher P. Paulson, MD, FaaFP
eglin	Family	Medicine	residency,	
eglin	Air	Force	Base,	Fla
Clinical commentary
Evidence-based answer
z Evidence summary
Guaifenesin, available in numerous prep-
arations (eg, Mucinex, Robitussin), is one 
of the most commonly used over-the-
counter medications in pregnancy. The 
National Birth Defects Prevention Study 
surveyed 2970 pregnant women from 
1997 to 2001; 6.2% reported taking guai-
fenesin during pregnancy.1 A second sur-
vey evaluated 7563 mothers from 1998 
to 2004; 9.2% of the mothers reported 
that they took it during pregnancy.1 
A weak link to inguinal hernias
Guaifenesin use in pregnancy has been 
associated with inguinal hernias in new-
borns. From 1958 to 1965, the Collabor-
ative Perinatal Project recruited 132,500 
women to participate in a multicenter 
study; however, selection and exclusion 
criteria were not consistent. From this 
initial group, only 50,282 mother-child 
pairs were studied. Trained examiners in-
terviewed the women at the child’s 4, 8, 
12, and 24-month visits, and then annu-
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ally thereafter to 8 years of age. 
The examiners identified 7 children 
with inguinal hernias among 197 mothers 
who had used guaifenesin during their first 
trimester (standardized relative risk [RR] 
of 2.6; no CI or P value reported). Twenty 
children had inguinal hernias among the 
1337 mothers who had used guaifenesin 
during any trimester of their pregnancy 
(RR=1.1; no confidence interval [CI] or 
P value reported).2 The authors acknowl-
edged that reporting bias among the par-
ticipating centers prevented them from 
drawing any conclusions from the data.
A possible trend toward  
neural tube defects?
Guaifenesin use in pregnancy may also 
be associated with neural tube defects. 
In a case-control study, researchers iden-
tified 538 fetuses and live-born infants 
with neural tube defects between 1989 
and 1991.3 Twelve patients with neural 
tube defects were exposed to guaifenesin 
during gestation; 6 in the control group 
reported exposure. 
The authors reported a trend towards 
increased risk of neural tube defects in 
offspring of guaifenesin-exposed mothers 
(odds ratio=2.04; 95% CI, 0.79–5.28).3 
However, since the results were not statis-
tically significant, the authors concluded 
that guaifenesin had not contributed to 
the occurrence of neural tube defects.
In a study evaluating 6509 women 
whose pregnancies resulted in live births, 
241 women reported first-trimester expo-
sure to guaifenesin.4 Five of the guaifen-
esin-exposed infants (2.1%) had 1 of the 
birth defects studied (types of disorders 
not reported). The calculated RR of birth 
defect after in utero guaifenesin exposure 
was 1.3 (no CIs or P values reported); 
the authors concluded that there was no 
strong association between guaifenesin 
and the malformations studied.4
Interpret results with caution
Because of the significant potential for 
recall bias, interpret the findings of these 
case-control studies with caution.5 The 
mother of a child with a birth defect may 
search her memory more aggressively 
for potential causes than a mother of a 
healthy infant, leading to different rates 
of recalled, rather than actual, exposures. 
In the absence of confirmatory prospec-
tive data, such as medication diaries or 
pharmacy databases, recall bias accounts 
for many spurious positive findings in 
case control studies.
Recommendations from others
food and Drug Administration. The FDA 
assigned guaifenesin to category C—that 
is, its risk cannot be ruled out. Human 
studies are lacking, and animal studies 
are either positive for fetal risk or lack-
ing. Guaifenesin is recommended if the 
benefit to the pregnant woman warrants 
the risk to the fetus.6 
ACoG. The American College of Ob-
stetricians and Gynecologists (ACOG) 
makes no recommendation.7 The text-
book Drugs in Pregnancy and Lactation 
reports that guaifenesin use during preg-
nancy exhibits very low risk to the fetus.6 
The National Collaborating Centre for 
Women’s and Children’s Health suggests 
that guaifenesin be used sparingly during 
pregnancy.8  n
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evidence, it seems 
prudent to avoid 
guaifenesin in  
the first trimester
